L and J-HZ is under clinical development by L&J Bio and currently in Phase I for Herpes Zoster (Shingles).
Adaptimmune loses $3B biobucks pact with Genentech
Roche’s Genentech has broken off its collaboration and license agreement on off-the-shelf T cell therapies with Adaptimmune. The pullback means Adaptimmune could miss out on